Valbiotis SA (FR:ALVAL) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Valbiotis announced the success of its INSIGHT clinical study, demonstrating that TOTUM•854 significantly reduces systolic blood pressure in individuals with untreated mild hypertension. This success marks TOTUM•854 as a promising non-drug solution for cardiovascular disease prevention, aligning with Valbiotis’ mission to improve health through innovative plant-based products.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.